Literature DB >> 33453304

MicroRNAs: Emerging oncogenic and tumor-suppressive regulators, biomarkers and therapeutic targets in lung cancer.

Shengjie Tang1, Shuangjiang Li2, Tao Liu1, Yiwei He3, Haiyang Hu1, Yunhe Zhu1, Shoujun Tang4, Haining Zhou5.   

Abstract

Lung cancer is one of the most common solid tumors worldwide and the leading cause of cancer-related deaths, causing a devastating impact on human health. The clinical prognosis of lung cancer is usually restricted by delayed diagnosis and resistance to anticancer therapies. MicroRNAs, a range of small endogenous noncoding RNAs 22 nucleotides in length, have emerged as one of the most important players in cancer initiation and progression in recent decades. Current evidence reveals pivotal roles of microRNAs in regulating cell proliferation, migration, invasion and metastasis in lung cancer. An increasing number of preclinical and clinical studies have also explored the potential of microRNAs as promising biomarkers and new therapeutic targets for lung cancer. The current review summarizes the most recent progress on the functional mechanisms of microRNAs involved in lung cancer development and progression and further discusses the clinical application of miRNAs as putative therapeutic targets for molecular diagnosis and prognostic prediction in lung cancer.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apoptosis; Biomarkers; Cell proliferation; Epithelial to mesenchymal transition; Lung cancer; Metastasis; MicroRNAs; Therapeutic targets

Year:  2021        PMID: 33453304     DOI: 10.1016/j.canlet.2020.12.040

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  16 in total

1.  Immune checkpoints related-LncRNAs can identify different subtypes of lung cancer and predict immunotherapy and prognosis.

Authors:  Hongpan Zhang; Meihan Liu; Guobo Du; Bin Yu; Xiaojie Ma; Yan Gui; Lu Cao; Xianfu Li; Bangxian Tan
Journal:  J Cancer Res Clin Oncol       Date:  2022-03-17       Impact factor: 4.553

2.  Methyltransferase-like 3 facilitates lung cancer progression by accelerating m6A methylation-mediated primary miR-663 processing and impeding SOCS6 expression.

Authors:  Shengshu Li; Xiaoxin Lu; Dongyang Zheng; Weizong Chen; Yuzhu Li; Fang Li
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-30       Impact factor: 4.322

3.  Human miRNAs to Identify Potential Regions of SARS-CoV-2.

Authors:  Nimisha Ghosh; Indrajit Saha; Nikhil Sharma; Jnanendra Prasad Sarkar
Journal:  ACS Omega       Date:  2022-06-07

4.  miR-18a-5p derived from mesenchymal stem cells-extracellular vesicles inhibits ovarian cancer cell proliferation, migration, invasion, and chemotherapy resistance.

Authors:  Xiaoying Wang; Lili Jiang; Qifang Liu
Journal:  J Transl Med       Date:  2022-06-07       Impact factor: 8.440

Review 5.  Next-Generation Sequencing with Liquid Biopsies from Treatment-Naïve Non-Small Cell Lung Carcinoma Patients.

Authors:  Paul Hofman
Journal:  Cancers (Basel)       Date:  2021-04-23       Impact factor: 6.639

6.  Construction of Competitive Endogenous RNA Network and Verification of 3-Key LncRNA Signature Associated With Distant Metastasis and Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma.

Authors:  Yang Su; Tianxiang Zhang; Jieqiong Tang; Li Zhang; Song Fan; Jun Zhou; Chaozhao Liang
Journal:  Front Oncol       Date:  2021-03-24       Impact factor: 6.244

7.  Radiotherapy-induced enrichment of EGF-modified doxorubicin nanoparticles enhances the therapeutic outcome of lung cancer.

Authors:  Jing Wang; Yan Zhang; GuangPeng Zhang; Li Xiang; HaoWen Pang; Kang Xiong; Yun Lu; JianMei Li; Jie Dai; Sheng Lin; ShaoZhi Fu
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

8.  Plasma extracellular vesicle microRNA profiling and the identification of a diagnostic signature for stage I lung adenocarcinoma.

Authors:  Shugeng Gao; Wei Guo; Tiejun Liu; Naixin Liang; Qianli Ma; Yibo Gao; Fengwei Tan; Qi Xue; Jie He
Journal:  Cancer Sci       Date:  2021-12-06       Impact factor: 6.716

9.  Altered Expressions of NF1 and NF1-Related microRNAs as Biomarkers in the Diagnosis of Undifferentiated Pleomorphic Sarcoma.

Authors:  Peng Zhang; Lingling Huang; Pengwei Ma; Xiaoying Niu
Journal:  Front Genet       Date:  2022-04-26       Impact factor: 4.772

Review 10.  MiRNAs in Lung Cancer: Diagnostic, Prognostic, and Therapeutic Potential.

Authors:  Javaid Ahmad Wani; Sabhiya Majid; Zuha Imtiyaz; Muneeb U Rehman; Rana M Alsaffar; Naveed Nazir Shah; Sultan Alshehri; Mohammed M Ghoneim; Syed Sarim Imam
Journal:  Diagnostics (Basel)       Date:  2022-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.